ScholarLens Back to search
2005•China Journal of EndoscopyRequires access

Transurethral plasmakinetic vaporization of prostate for treatment of benign prostate hyperplasia (report of 120 cases)

LI Fan-bin

Open publisher page 0 citations

Abstract

[Objective] To discuss the safety and efficacy of transurethral plasmakinetic vaporization of prostate(TUPKVP). [Methods] 120 patients with symptomatic BPH were threated by TUPKVP. [Results] Less blood loss and no transurethral resection syndrom and permanent urinary incontinence. All Patients were followed up of 1~9 months postoperatively. The peak flow rate increased from 8.6 mL/s to 19.8 mL/s. The IPSS decreased from 26 to 9.6. Residual urine avolume decreased from 73 mL to 10.0 mL. [Conclusions] TUPKVP has the advantages of high safety, less complications and good efficacy.

About this research paper

What this paper is about

[Objective] To discuss the safety and efficacy of transurethral plasmakinetic vaporization of prostate(TUPKVP). [Methods] 120 patients with symptomatic BPH were threated by TUPKVP. [Results] Less blood loss and no transurethral resection syndrom and permanent urinary incontinence. All Patients were followed up of 1~9 months postoperatively. The peak flow rate increased from 8.6 mL/s to 19.8 mL/s. The IPSS decreased from 26 to 9.6. Residual urine avolume decreased from 73 mL to 10.0 mL. [Conclusions] TUPKVP has the advantages of high safety, less complications and good efficacy.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

[Objective] To discuss the safety and efficacy of transurethral plasmakinetic vaporization of prostate(TUPKVP). [Methods] 120 patients with symptomatic BPH were threated by TUPKVP. [Results] Less blood loss and no transurethral resection syndrom and permanent urinary incontinence. All Patients were followed up of 1~9 months postoperatively. The peak flow rate increased from 8.6 mL/s to 19.8 mL/s. The IPSS decreased from 26 to 9.6. Residual urine avolume decreased from 73 mL to 10.0 mL. [Conclusions] TUPKVP has the advantages of high safety, less complications and good efficacy.

Key concepts: Medicine, Urology, Hyperplasia, Prostate, Vaporization, Urine flow rate, Blood loss, Transurethral resection of the prostate

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Transurethral plasmakinetic vaporization of prostate for treatment of benign prostate hyperplasia (report of 120 cases) — Research Paper | ScholarLens